reports
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on December 1, 2025 to two new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), ...
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonst...
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain -- New data published in Pain Physician shows significant improvement in functional outcomes with iovera° ---- Fewer iovera° patients required additional spine injections after 180 days ---- No treatment-related adverse events were reported -- BRISBANE, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver inn...
Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against...
Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical -- Lawsuit triggers 30-month stay under the Hatch Waxman Act -- BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has filed a patent infringement lawsuit in the United States District Court for the District of Delaware against The WhiteOak Group, Inc. and Qilu Pharmaceutical (Hainan) Co., ...
Pacira Biosciences Inc: 1 director
A director at Pacira Biosciences Inc sold 12,060 shares at 22.090USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Hea...
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences BRISBANE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: Jefferies London Healthcare Conference on Tuesday, November 18th at 1:30PM GMT (8:30AM ET).37th Annual Piper Sandler Healthcare Conference on Tuesday, December 2nd at 1:3...
Pacira BioSciences Reports Third Quarter 2025 Financial Results; Incre...
Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance -- Third quarter revenues up 6% driven by EXPAREL volume growth of 9% -- -- Several key milestones advance 5x30 path to growth and value creation -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the third quarter of 2025. Third Quart...
Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 S...
Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee -- Milestone advances two-part study evaluating novel, locally administered gene therapy designed to increase anti-inflammatory IL-1Ra production in the knee joint -- BRISBANE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has concluded patient...
Pacira BioSciences Enters Exclusive License Agreement with AmacaThera ...
Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control -- Advances 5x30 strategy by expanding pipeline with a highly complementary asset that has the potential to provide several days of pain control -- -- Phase 2 program for AMT-143 expected to begin in 2026 -- BRISBANE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced an exclusive wor...
Pacira to Report Third Quarter 2025 Financial Results on Thursday Nove...
Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025 BRISBANE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its third quarter financial results after the close of the U.S. markets on Thursday November 6, 2025. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and an...
Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sust...
Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee -- Data demonstrates sustained clinical improvements in pain, stiffness and function for up to 156 weeks following a single administration of PCRX-201 -- BRISBANE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced updated three-year results and a ...
Pacira BioSciences Notified of Abbreviated New Drug Application Filing...
Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL® BRISBANE, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients today reported it has received a Paragraph IV Certification Notice Letter (PIV Notice) from Qilu Pharmaceutical (Hainan) Co., Ltd., a private Chinese company. Qilu has filed an Abbreviated New Drug Application, or ANDA, with the FDA for a product claim...
Pacira BioSciences to Present New Data from Three Real-World Studies w...
Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL® -- Findings Presented at AMCP Nexus 2025 Annual Meeting -- BRISBANE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced real-world evidence evaluating the clinical effectiveness and economic benefits of EXPAREL® (bupivacaine liposome injectable suspension) will be presented at the AMCP Nexus 2025 Annual Meeting taking place October 27–30 in Natio...
Pacira BioSciences Notified of Abbreviated New Drug Application Filing...
Pacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL® BRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients today reported it has received a Paragraph IV Certification Notice Letter (PIV Notice) from The WhiteOak Group, a subsidiary of a small private Chinese company. WhiteOak has filed an Abbreviated New Drug Application, or ANDA, with the FDA for a product claiming to be a ge...
Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain...
Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy -- Poster to be presented at American College of Rheumatology Convergence 2025 – BRISBANE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that new from its Phase 1 clinical trial evaluating PCRX-201 (enekinragene inzadenovec), a novel gene therapy candid...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on October 2, 2025 to 15 new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), th...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on September 3, 2025 to nine new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4...
Pacira BioSciences Reports Second Quarter 2025 Financial Results
Pacira BioSciences Reports Second Quarter 2025 Financial Results -- Solid execution across corporate, clinical and commercial initiatives -- -- Several key milestones advance 5x30 path to growth -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the second quarter of 2025. Second Quarter 2025 Financial Highlights Total revenues of $181.1 m...
Pacira to Report Second Quarter 2025 Financial Results on Tuesday Augu...
Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025 BRISBANE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its second quarter financial results after the close of the U.S. markets on Tuesday August 5, 2025. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answ...
Pacira BioSciences Announces Strategic Collaboration to Significantly ...
Pacira BioSciences Announces Strategic Collaboration to Significantly Expand ZILRETTA Promotional Efforts Partnership expected to advance 5x30 strategy by increasing ZILRETTA sales calls and extensively expanding patient access BRISBANE, CA, July 22, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced a strategic collaboration1 with Johnson & Johnson MedTech to significantly expand the market reach of ZILRETTA® (triamcinolone acetonide extended-...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on July 2, 2025 to seven new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), th...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.